- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | 100 | GlobeNewswire (Europe) | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| 25.09. | Silexion regains Nasdaq compliance, advances cancer therapy program | 1 | Investing.com | ||
| 25.09. | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | 100 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 25.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data | 5 | Benzinga.com | ||
| 11.09. | Silexion Therapeutics announces pricing of $6M public offering | 3 | Seeking Alpha | ||
| 11.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion-Aktie schießt nach positiven Daten zu Krebsmedikament um 400 % in die Höhe | 5 | Investing.com Deutsch | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Silexion stock soars 400% after positive pancreatic cancer drug data | 2 | Investing.com | ||
| 11.09. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration | 125 | GlobeNewswire (Europe) | New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation... ► Artikel lesen | |
| 05.09. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 04.09. | Silexion beauftragt AMS als CRO-Partner für klinische Studien zur KRAS-Krebstherapie | 1 | Investing.com Deutsch | ||
| 04.09. | Silexion selects CRO partner for upcoming KRAS cancer therapy trials | 2 | Investing.com | ||
| 04.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 | 4 | GlobeNewswire (USA) | ||
| 02.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 20.08. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.08. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Silexion Therapeutics reports Q2 results | 4 | Seeking Alpha |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,10 | +2,11 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CUREVAC | 4,626 | +0,09 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 259,70 | +0,78 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,273 | -0,29 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 134,85 | +0,67 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,130 | +3,38 % | Novo Nordisk, Eli Lilly oder Viking Therapeutics: Wer gewinnt den Dreikampf? | Der Markt für Adipositas-Medikamente boomt - und die Konkurrenz zwischen den Schwergewichten Novo Nordisk und Eli Lilly prägt das Geschehen. Doch während sich die Giganten duellieren, könnte das viel... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,430 | +2,97 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 79,00 | +1,28 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| BIOCRYST PHARMACEUTICALS | 6,634 | +4,34 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,270 | +2,16 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 46,830 | +0,86 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 34,490 | +2,83 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 %, Markteinführung bei NET gewinnt an Fahrt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,037 | +0,10 % | Cathie Wood's ARK ETFs buy DraftKings, Pacific Biosciences stock | ||
| CARDIOL THERAPEUTICS | 0,998 | +4,07 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.